The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats

被引:23
作者
Ahnaou, A [1 ]
Megens, AAHP [1 ]
Drinkenburg, WHIM [1 ]
机构
[1] Johnson & Johnson Consumer Prod Inc, Pharmaceut Res & Dev, Dept CNS Discovery Res, B-2340 Beerse, Belgium
关键词
antipsychotic; quantitative EEG analysis; sedation; rat; risperidone; clozapine; olanzapine;
D O I
10.1159/000071829
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The atypical antipsychotics risperidone, clozapine and olanzapine were studied for their ability to antagonise apomorphine-induced stereotypy and to affect electroencephalographic (EEG) activity in rats. The compounds antagonised apomorphine-induced stereotypy with ED(50)s of 0.15 mg/kg s.c. for risperidone, 0.42 mg/kg s.c. for olanzapine and 1.3 mg/kg s.c. for clozapine. At a dose close to that required for apomorphine antagonism (0.16 mg/kg s.c.), risperidone induced only minor changes in EEG power spectral activity. At a higher dosage (0.63 mg/kg s.c.) it increased the power density in the high frequency range (9.8-18.6 Hz), characteristic of a sedative-like effect. Olanzapine and clozapine caused a dose-dependent increase in power density in all frequency bands. These effects were already present at doses (0.04 and 0.16 mg/kg s.c., respectively) 10 times below those required for apomorphine antagonism. The effects increased dose-dependently and were pronounced at the doses required for apomorphine antagonism. These results in rats are in agreement with the clinical observation that risperidone has less propensity for inducing sedation at therapeutic dose levels than olanzapine and clozapine. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 39 条
[21]   ELECTROENCEPHALOGRAPHIC CORRELATES OF THE SEDATIVE EFFECTS OF DOPAMINE AGONISTS PRESUMABLY ACTING ON AUTORECEPTORS [J].
KROPF, W ;
KUSCHINSKY, K .
NEUROPHARMACOLOGY, 1991, 30 (09) :953-960
[22]   Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers [J].
Lee, DY ;
Lee, KU ;
Kwon, JS ;
Jang, IJ ;
Cho, MJ ;
Shin, SG ;
Woo, JI .
PSYCHOPHARMACOLOGY, 1999, 144 (03) :272-278
[23]  
LEYSEN JE, 1988, J PHARMACOL EXP THER, V247, P661
[24]   SPECTRUM OF EEG ABNORMALITIES DURING CLOZAPINE TREATMENT [J].
MALOW, BA ;
REESE, KB ;
SATO, S ;
BOGARD, PJ ;
MALHOTRA, AK ;
SU, TP ;
PICKAR, D .
ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1994, 91 (03) :205-211
[25]   SURVEY ON THE PHARMACODYNAMICS OF THE NEW ANTIPSYCHOTIC RISPERIDONE [J].
MEGENS, AAHP ;
AWOUTERS, FHL ;
SCHOTTE, A ;
MEERT, TF ;
DUGOVIC, C ;
NIEMEGEERS, CJE ;
LEYSEN, JE .
PSYCHOPHARMACOLOGY, 1994, 114 (01) :9-23
[26]  
MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238
[27]  
Miller DD, 2000, J CLIN PSYCHIAT, V61, P14
[28]   EFFECTS OF REMOXIPRIDE, A DOPAMINE D-2 ANTAGONIST ANTIPSYCHOTIC, ON SLEEP-WAKING PATTERNS AND EEG ACTIVITY IN RATS AND RABBITS [J].
ONGINI, E ;
BO, P ;
DIONISOTTI, S ;
TRAMPUS, M ;
SAVOLDI, F .
PSYCHOPHARMACOLOGY, 1992, 107 (2-3) :236-242
[29]  
ONGINI E, 1993, J PHARMACOL EXP THER, V266, P726
[30]  
ONGINI E, 1989, INT REV NEUROBIOL, V31, P239